SEC Form 4 · accession 0001209191-18-063350
HERON THERAPEUTICS, INC. /DE/ · HRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly Manhard
Officer — Executive VP, Drug Development
Period of report
Dec 15, 2018
Accepted (ET)
Dec 18, 2018 · 8:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818033
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $24.97 | Dec 15, 2018 | A | 100,000 | A | — | Dec 15, 2028 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant.